Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
复制标题

DOI:
10.1038/ncomms3854
复制
发表时间:
2013
影响因子:
16.6
通讯作者:
Bouvier, Nicole M.
Bouvier, Nicole M.
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Hai, Rong;Schmolke, Mirco;Leyva-Grado, Victor H.;Thangavel, Rajagowthamee R.;Margine, Irina;Jaffe, Eric L.;Krammer, Florian;Solorzano, Alicia;Garcia-Sastre, Adolfo;Palese, Peter;Bouvier, Nicole M.

文献摘要

参考文献

被引文献

相似文献

没有基线的人类对紧急禽流感A(H7N9)病毒的免疫力,神经氨酸酶抑制剂对于控制严重感染中的病毒复制至关重要。在一些H7N9临床分离株中发现了与耐药性相关的病毒神经氨酸酶NA-R292K(N2编号)的氨基酸变化。在这里,我们评估了NA-R292K替换对H7N9病毒的抗病毒敏感性和病毒复制、致病性和传播性的影响。我们的数据表明,编码NA-R292K替换的H7N9分离株对奥司他韦和帕拉米韦高度耐药,对扎那米韦部分耐药。此外,具有和不具有耐药性突变的H7N9重组体在原代人类呼吸道细胞中显示出类似的病毒复制、在小鼠中的毒力和在豚鼠中的传播性。因此,与耐奥司他韦的季节性甲型流感病毒(H3N2)形成鲜明对比的是,由于NA-R292K突变而获得高水平的奥司他韦耐药性,并没有实质上改变H7N9病毒在这些模型中的复制和致病性。一些甲型H7N9流感病毒临床分离株编码神经氨酸酶突变,可能对唯一有效的抗H7N9药物产生耐药性。在这里,作者表明,这种突变不会影响病毒的复制和致病性,同时在体内调节对抗病毒药物的耐药性。
Without baseline human immunity to the emergent avian influenza A(H7N9) virus, neuraminidase inhibitors are vital for controlling viral replication in severe infections. An amino acid change in the viral neuraminidase associated with drug resistance, NA-R292K (N2 numbering), has been found in some H7N9 clinical isolates. Here we assess the impact of the NA-R292K substitution on antiviral sensitivity and viral replication, pathogenicity and transmissibility of H7N9 viruses. Our data indicate that an H7N9 isolate encoding the NA-R292K substitution is highly resistant to oseltamivir and peramivir and partially resistant to zanamivir. Furthermore, H7N9 reassortants with and without the resistance mutation demonstrate comparable viral replication in primary human respiratory cells, virulence in mice and transmissibility in guinea pigs. Thus, in stark contrast to oseltamivir-resistant seasonal influenza A(H3N2) viruses, H7N9 virus replication and pathogenicity in these models are not substantially altered by the acquisition of high-level oseltamivir resistance due to the NA-R292K mutation. Some clinical isolates of influenza A(H7N9) virus encode a mutation within neuraminidase that could confer resistance to the only class of drugs active against H7N9. Here, the authors show that this mutation does not affect viral replication and pathogenicity while mediating resistance to antivirals in vivo.
人类感染新型禽源甲型流感 (H7N9) 病毒。
DOI: 10.1056/nejmoa1304459
发表时间: 2013-05-16
影响因子: 158.5
作者:
Gao, Rongbao;Cao, Bin;Shu, Yuelong
通讯作者: Shu, Yuelong
DOI: 10.1371/journal.ppat.1001015
发表时间: 2010-07-22
期刊: PLoS pathogens
影响因子: 6.7
作者:
Hamelin ME;Baz M;Abed Y;Couture C;Joubert P;Beaulieu E;Bellerose N;Plante M;Mallett C;Schumer G;Kobinger GP;Boivin G
通讯作者: Boivin G
DOI: 10.1128/aem.16.4.588-594.1968
发表时间: 1968-01-01
期刊: APPLIED MICROBIOLOGY
影响因子: --
作者:
GAUSH, CR;SMITH, TF
通讯作者: SMITH, TF
新型甲型 H7N9 流感病毒引起的人类疾病不良临床结果与持续病毒脱落和抗病毒耐药性出现之间的关联
DOI: 10.1016/s0140-6736(13)61125-3
发表时间: 2013-06-29
期刊: LANCET
影响因子: 168.9
作者:
Hu, Yunwen;Lu, Shuihua;Yuan, Zhenghong
通讯作者: Yuan, Zhenghong
DOI: 10.1128/jvi.07242-12
发表时间: 2012-07-01
影响因子: 5.4
作者:
Bouvier, Nicole M.;Rahmat, Saad;Pica, Natalie
通讯作者: Pica, Natalie